Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.
source https://www.sciencedaily.com/releases/2025/01/250125152749.htm
Webb spots the birth of a giant galaxy and a supermassive black hole
-
Astronomers have used the James Webb Space Telescope to catch an
extraordinary glimpse of a massive galaxy taking shape in the early
universe. They identif...
5 hours ago
Welcome to the 'The Fact Factory' friends. Its an interesting Hot Spot which brings to you amazing and little known facts from all over the world. So, sit back, take a tour around the world and enjoy the trivia.
No comments:
Post a Comment